• Our Team
  • GP Symposium 2025
  • GP Heart Blog
  • Patient Info
  • New patient form
  • Contact
Menu

Cardiology Institute

Unit 109, 119 Apollo Drive, Albany, Auckland
consult@cardiologist.co.nz
P: xxx-xxxx; F xxx-xxxx
Unit 109, 119 Apollo Drive, Albany, Auckland. P: 000-0000. F: 000-0000. consult@cardiologist.co.nz. EDI: cardinst

T 09-980-6363. M 022-672-8255. F 09-929-3248. consult@cardiologist.co.nz. EDI: CARDINST

North Shore - Suite 109, Level 1, 119 Apollo Drive, Albany

Silverdale - Northern Specialist Centre @Beyond; 5 Painton Road, Silverdale.

Central Auckland - 110 Specialist Centre @ Beyond;v110 Grafton Road, Grafton

East Auckland - East Care Specialist Centre, 260 Botany Road, Howick, Manukau

Cardiology Institute

  • Our Team
  • GP Symposium 2025
  • GP Heart Blog
  • Patient Info
  • New patient form
  • Contact

Beta-blockers in Hypertension

September 5, 2019 Andrew To

Case

70-year-old asymptomatic man with hypertension but not cardiovascular disease presented for a routine check. His pulse rate was 40bpm.  His son, aged 45, recently had an MI in Australia.

His medications include

-       Doxazosin 8mg OD

-       Metoprolol 95mg CR OD – since 2006

-       Cilazapril 5mg / Hydrochlorothiazide 12.5mg OD

ECG shows sinus bradycardia, with normal PR interval, QRS duration.

Discussion

Without proven cardiovascular disease, in particular, angina and/or heart failure, the role of beta-blockers for hypertension is debatable.  Even though he is asymptomatic from the sinus bradycardia, it would be useful to adjust his medications with less beta-blockade, and introduce calcium channel blocker.

First line agents for hypertension are one of three classes:

-       ACE inhibitors or Angiotensin receptor blockers

-       Thiazides

-       Calcium channel blockers

There may be some advantage of using ACEi/ARB in the young vs. CCB/thiazides in the older population where isolated systolic hypertension is more prevalent.

β-blocker is generally NOT preferred as first line agent. (JNC8) The exceptions are in the settings of post-myocardial infarction, and heart failure.

Drug preference is mainly influenced by co-morbidities and contraindications, rather than a simple age cut-off. 

 

Author: Dr Andrew To

In Drug Treatment Tags hypertension, beta-blocker, calcium channel blocker, ACE inhibitor, angina, coronary artery disease, heart failure
← Hypertension treatment – how should we choose?BP therapy initiation - Combination vs. Single Agent →

Copyright @2024 Cardiology Institute; All photos copyright @2024 Andrew To